



Teaser This review describes approaches to identify and optimize small molecules interacting with RNA.



Methods to identify and optimize small molecules interacting with RNA (SMIRNAs)

Andrei Ursu, Simon Vézina-Dawod and Matthew D. Disney

Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, Jupiter, FL 33458, USA


RNAs, particularly noncoding RNAs (ncRNAs), are becoming increasingly important therapeutic targets, because they are causative and antagonists of human disease. Indeed, aberrant RNA structural elements and expression deregulate biological processes. In this review, we describe methodologies to discover and optimize small molecules interacting with RNA (SMIRNAs), including the evaluation of direct target engagement and the rescue of RNA-mediated phenotypes *in vitro* and *in vivo*. Such studies are essential to fully characterize the mode of action of SMIRNAs and advance our understanding of rationally and efficiently drugging RNAs for therapeutic benefit.

Introduction

Most drug discovery campaigns focus on modulating defective or aberrantly expressed protein targets, enabled by technological advancements in high-throughput screening (HTS), protein-biased small-molecule compound libraries, assessment of direct target engagement in cells, and structure determination. By and large, these technologies are less developed for RNA targets. The identification of RNAs as key pathological agents in many diseases and the serendipitous discovery that small molecules identified from phenotypic screens act on the RNA [1] or pre-mRNA and the RNA/spliceosome interface [2,3] support the notion of targeting RNA for therapeutic benefit. Indeed, advances in structural determination of RNA and RNA-protein and/or small-molecule complexes [4] have revealed that RNAs exhibit well-defined druggable pockets thought to be reserved for protein targets. Alternatively, targetable sites in RNA could be highly flexible or dynamic [5], providing a transient structure that could accommodate or be stabilized by small molecules, akin to an induced-fit model used to describe some protein–small-molecule interactions.

Until recently, few RNAs had been investigated as potential drug targets, such as bacterial ribosomes, RNAs found in pathogenic yeast and/or fungi, and viral RNAs, such as HIV-1 TAR [6,7]. Recent breakthroughs showed that various disorders, such as Huntington's disease (HD), myotonic dystrophy type 1 (DM1), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD), are triggered by RNA repeat expansions, such as r(CAG)^{exp}, r(CUG)^{exp}, and r(G₄C₂)^{exp}, respectively. These feature well-defined RNA secondary structures, and their contribution to

Andrei Ursu was awarded his PhD in chemical biology under the supervision of Herbert Waldmann at the Max Planck Institute of Molecular Physiology, Dortmund, Germany, focusing on chemical reprogramming of stem cells with small molecules. In 2016, Dr Ursu moved to the Scripps Research Institute in Florida as a postdoctoral fellow in the lab of Matthew D. Disney, where he works on the development of small-molecule RNA therapeutics targeting GGGGCC repeat expansions that cause amyotrophic lateral sclerosis (ALS).



Simon Vézina-Dawod was awarded his PhD in Pharmaceutical sciences in 2018 at the Faculty of Pharmacy Université Laval, Québec, Canada, where he conducted research in Eric Biron's laboratory, developing novel approaches to generate highly diversified heterocycle libraries using multicomponent reactions. He also worked on the development of novel One-Bead-One-Compound methodologies to efficiently address the combinatorial chemistry of pseudopeptide macrocycles to target protein–protein interactions. After receiving his PhD, Dr Vézina-Dawod joined Matthew D. Disney's group as a postdoctoral fellow at The Scripps Research Institute in Florida to conduct research on developing new screening methodologies to target RNAs.



Matthew D. Disney had his early schooling in the Baltimore Catholic school system and earned his PhD in chemistry from the University of Rochester in 2003 under Douglas Turner, conducting research on RNA folding, biochemistry of group I introns, and computational prediction of RNA secondary structure. He then explored carbohydrate polymers for the development of microarrays as a postdoctoral fellow in the lab of Peter Seeberger at MIT and ETH Zürich. In 2009, he moved to The Scripps Research Institute, Florida, where he was appointed to full professor in 2014. His research interests are focused on the rational design of small molecules and chemical probes targeting disease-causing RNAs.



Corresponding author: Disney, M.D. (D)

disease emergence have been thoroughly investigated, substantiating even further the necessity of considering RNA as a *bona fide* drug target. Yet, these examples represent a tiny fraction of the underexplored and therapeutically relevant RNA biological space. Indeed, the results of the Encyclopedia of DNA Elements (ENCODE) project revealed that most of the transcriptome does not translate into proteins and, therefore, is noncoding [8]. Recent developments in RNA sequencing [9], prediction of RNA secondary structure from sequence [10], as well as determination of RNA structures in cells [11,12] are adding more evidence of the structural and functional roles of ncRNAs, such as miRNAs and long ncRNAs (lncRNAs) in the progression of various human diseases. Indeed, increasing amounts of evidence [13–16] emphasize that biological activity is controlled by various RNA secondary structure elements (RNA motifs) within ncRNAs, the modulation of which with small molecules might lead to the development of novel lead medicines.

Herein, we review developments of small molecules and chemical probes [17–19] targeting key RNA structural elements from HIV-1, pathogenic yeasts, and microsatellite repeat expansions as well as emerging ncRNAs, such as miRNAs and lncRNAs. We focus on the key screening technologies and/or methodologies that successfully identified small molecules targeting the disease-causing RNA structural elements. Whenever applicable, we describe the optimization process of the initial hit together with the mode of binding of the small molecule to the target RNA. In addition, we emphasize the importance of translating the *in vitro* results to the physiologically relevant cellular models of the disease-causing ncRNA by applying recently developed target engagement techniques. Confirming the RNA-centric mode of action of the small molecules is vital to develop selective chemical probes and tools that efficiently modulate ncRNA function *in vitro* and *in vivo*. Therefore, we further discuss recent advances in the modular assembly of inhibitors *in situ* templated by RNA structural elements as well as small molecules that cleave RNA targets. Collectively, these efforts have the potential to open new avenues in drug discovery by providing novel therapeutic opportunities for diseases, the pathology of which is triggered by disease-causing RNAs.

Structure-based design strategies

Characterization of RNA–protein macromolecular complexes represents a rich source of structural information, fostering an in-depth understanding of the molecular recognition events and their impact on biological processes. High-resolution structures can reveal atomistic details of the RNA–protein binding interface, showing the key amino acids that drive the macromolecular complex formation. Therefore, mimicking these interactions can represent the basis for the rational design of peptides, peptidomimetics, and macrocycles as RNA binders.

Structure-guided design of macrocycles targeting HIV-1 TAR

The *trans*-activator protein (Tat) and the *trans*-activation response element (TAR) RNA interaction is crucial for the viral replication of HIV-1 and, therefore, is steadily pursued for the development of novel antiviral agents. Shortridge *et al.* [20] reported the structural-guided optimization of L22, a conformationally constrained β -hairpin-containing peptide derived from the arginine-

rich motif (ARM) of the Bovine Immunodeficiency Virus (BIV) Tat–TAR complex. A focused positional scanning strategy with noncanonical amino acids was applied to the BIV ARM-derived peptide L22, which yielded the macrocyclic peptide JB181 (Fig. 1a), a picomolar affinity and selective binder of TAR RNA even in large excess of tRNA competitor. The strong interaction yielded a 1.4 Å resolution NMR structure that confirmed the key residues driving the peptide–RNA interaction (Fig. 1a). Despite the > 100-fold higher *in vitro* binding affinity of JB181 to the RNA target relative to the starting peptide L22, no significant difference in bioactivity was observed in various cellular assays. This discrepancy suggests a complex interplay of the conformational changes or stabilization occurring upon the protein–RNA interaction *in vitro* and their relevance in the assembly of multicomponent macromolecular complexes in cells. In conclusion, the report highlighted the potential of structure-guided optimization of cyclic peptides to generate subnanomolar binders of TAR RNA with good selectivity, which will aid efforts to develop novel and potent antivirals.

Nucleolin-derived peptide inhibitor targeting r(CAG)^{exp}

Numerous neurodegenerative disorders are triggered by trinucleotide repeat expansions [r(CAG)^{exp}], including Huntington's disease (HD), spinocerebellar ataxia type 2 (SCA2), and spinocerebellar ataxia type 3 (SCA3) [21]. Long stretches of r(CAG)^{exp} form a hairpin structure featuring 1 × 1 AA internal loops that sequester various RNA-binding proteins such as muscleblind-like protein 1 (MBNL1) and nucleolin (NCL) [21], which is in part responsible for the disease etiology. The interaction between NCL and r(CAG)^{exp} was previously characterized and is mediated by the RNA recognition motifs (RRMs) 2 and 3 of NCL. Therefore, by analyzing the binding interface of the r(CAG)^{exp} and RRM regions, truncated peptides can be derived as starting points for the design of novel r(CAG)^{exp} binders. However, compared with the protein domains they were derived from, peptides tend to be weaker binders and additionally suffer from various liabilities, such as cellular stability and permeability. Therefore, downstream optimization strategies, such as secondary structure rigidification, are further applied to circumvent these drawbacks.

Zhang *et al.* [22] reported the structure-guided optimization of a previously identified 13-amino acid peptide (P3) derived from the RRM2 domain of NCL. Given that P3 was predicted to adopt a flexible conformation without a defined secondary structure, optimization efforts led to a 21-mer peptide termed 'Beta-structured Inhibitor for Neurodegenerative Diseases' (BIND) (Fig. 1b) that folds into a β -hairpin-containing secondary structure. An alanine scan strategy throughout its sequence highlighted Glu2, Lys13, Gly14, Ile18, Glu19, and Phe20 as the key amino acids involved in the binding to r(CAG)^{exp}. To facilitate the translocation across the cellular membrane, the BIND peptide was conjugated with the 11-amino acid cell-penetrating transactivator of transcription (TAT) peptide. The TAT-BIND peptide rescued the cellular toxicity in r(CAG)₇₈-transfected HEK293 cells and reduced nucleolar stress by restoring the normal localization of NCL and nucleophosmin (NPM; B23) in the nucleoli. Interestingly, in *Drosophila* and a mouse striatal cell model of HD, the binding potency of the BIND peptide increased with the CAG repeat size and suppressed neurodegeneration *in vivo*. In conclu-

sion, the NCL-r(CAG)^{exp} interaction represents an excellent starting point in structure-guided campaigns to generate peptides binding r(CAG)^{exp}.

Virtual screening by exploiting RNA ensembles of HIV-1 TAR RNA

Structure-based (SB) approaches are emerging as essential tools that can cost- and time-efficiently accelerate drug discovery campaigns for RNA targets. Such strategies include the prediction, identification, and optimization of small molecules toward an RNA target of interest using the 3D structural information obtained by X-ray crystallography and/or NMR spectroscopy. Within SB drug discovery (SBDD) strategies, virtual screening (VS) enables docking of virtual chemical libraries of small molecules using a well-defined binding pocket or region of interest within an RNA structure. This process usually yields a set of possible binding poses as well as an estimation of their corresponding binding free energy. Therefore, VS represents an alternative to HTS campaigns, allowing a straightforward exploration of the chemical space at reduced costs. However, VS applied to even well-characterized RNA targets, such as HIV-1 TAR, is currently elusive and is mainly attributed to the inability to select the biologically relevant RNA conformation(s) [23] that the chemical libraries should be screened against. Therefore, the results of the screening campaign might vary depending on the quality of the RNA model as well as on the structural determination methodology used for generating it, hampering a clear-cut distinction of the true hits that can be further pursued experimentally.

Target-based approaches

Ganser *et al.* [24] reported a hybrid experimental–computational approach using RNA dynamic ensembles derived from HIV-1 TAR RNA. The authors employed a training set comprising 177 experimentally validated hit molecules, seven out of which were novel (Fig. 1c) and 103 349 nonbinders, as determined by HTS via a Tat-peptide displacement assay. VS was then performed on a dynamic ensemble of 20 equally populated HIV-1 TAR conformations obtained by NMR spectroscopy and molecular dynamics (MD) simulations. This ensemble-based VS (EBVS) approach overcomes the shortcomings of identifying experimentally validated hits because of either the number of individual conformations or poorly represented RNA ensembles lacking experimental confirmation in solution. True hits were enriched, and their enrichment correlated with the accuracy of the generated RNA ensemble as well as its size. Moreover, the ligand was placed in the proximity of the RNA binding motif as experimentally determined by NMR spectroscopy. In conclusion, the study emphasizes the importance of using RNA dynamic ensembles in VS campaigns to reduce the gap between *in silico* predictions and experimental validation.

Ligand-based approaches

A chemical-similarity search was used by Parkesh *et al.* [25] to identify r(CUG)^{exp} binders using Hoechst 33258 and pentamidine as queries using National Cancer Institute (NCI; 250 000 compounds) and eMolecules (8 000 000 molecules) databases. A robust 3D alignment software termed ‘Rapid Overlay of Chemical Structure’ (ROCS) straightforwardly sampled the two databases for novel derivatives that were chemically similar to the initially selected lead molecules. The most promising candidates were tested in various binding and functional assays *in vitro* and in a DM1 cellular model, respectively. These efforts yielded derivative

H1 that disrupted r(CUG)^{exp} nuclear foci and improved DM1 splicing defects both *in vitro* and *in vivo*.

Using a pharmacophore-based VS search, Angelbello *et al.* [26] identified novel compounds that target r(CUG)^{exp}. The authors built a pharmacophore model using a training set of ten known small-molecule binders of r(CUG)^{exp}. Then, novel chemotypes were identified within 4.3 million compounds with drug-like properties part of the ZINC database [27,28]. The selected candidates were validated to bind r(CUG)^{exp} *in vitro* and correct various phenotypes in cellular models of DM1. For example, derivative p7 stimulated the nucleocytoplasmic transport of r(CUG)^{exp} retained in the nucleus and improved pre-mRNA splicing defects associated with the sequestration of MBNL1.

In conclusion, these studies reveal important features of targeting RNA with small molecules. First, previously reported small molecules binding r(CUG)^{exp} represent excellent starting points for pharmacophore-based VS strategies to explore chemical space for novel chemotypes even in the absence of a thoroughly characterized RNA target. Second, integrating VS *in silico* with robust binding assays in a high-throughput format can rapidly delineate true hits that can subsequently be tested in physiologically relevant cell lines that best represent the disease-causing RNA under investigation.

Fluorescence-based screening strategies


HTS of compound libraries represents a well-established paradigm for the identification of small-molecule modulators of various biological targets. Among the possible readout formats, measuring fluorescence change informs the conformational changes in the vicinity of a fluorescently labeled RNA or RNA-binding ligands [29]. The ability to examine such processes in solution in a homogenous plate-format, at relatively low cost, across multiple time points or in an end-point fashion, makes the fluorescence readout readily applicable in target-based drug discovery HTS campaigns. For example, HTS of commercially available compound collections is routinely used as preliminary screen against fluorescently labeled RNA, using various formats, such as fluorescence polarization (FP), Förster resonance energy transfer (FRET), or in combination with fluorescent dyes, as in differential scanning fluorimetry (DSF) [30].

Inhibitors of group II intron via fluorescence-based enzymatic assays


An assay set-up readily applicable for enzymatic reactions relies on the turn-on fluorescence signal of a fluorescently quenched construct. For example, an oligonucleotide containing an Alexa555 fluorophore proximal to the Black Hole Quencher 2 (BHQ2) is fluorescently inactive because of the latter, which absorbs the excitation energy from the adjacent fluorophore [31]. However, the removal of this moiety from the oligonucleotide substrate induces an increase in the (turned-on) fluorescent signal, which makes this assay set-up well suited for the interrogation of RNA molecules with enzymatic activity, such as group II ribozymes. These represent intriguing self-splicing introns, the splicing of which is exclusively mediated by rearrangement of large RNA (sub)domains without the assistance of proteins [32]. These are unique RNA targets present within the mitochondrial genome of pathogenic yeasts, and their inhibition can directly impact the

Fluorescence-based screening strategies


(a) Fluorescence-based enzymatic assays




(b) Dye displacement assay on the $r(\text{G}_4\text{C}_2)^{\text{exp}}$ hairpin



(c) FRET-based melting assay on the $r(\text{G}_4\text{C}_2)^{\text{exp}}$ G-quadruplex



(d) Intrinsic fluorescence



Drug Discovery Today

FIGURE 2

Graphical representations of the fluorescence-based screening strategies used to identify small molecules interacting with RNA. **(a)** A fluorescently inactive oligonucleotide embedding AF555 fluorophore and BHQ2 quencher was designed to mimic the natural substrate cleaved by the group II self-splicing introns. Upon cleavage by the engineered D135 ribozyme, BHQ2 is released, leading to turn-on fluorescence signal. Initial hit compound 1 was optimized via medicinal chemistry approaches to the more potent derivative Intronistat B. **(b)** The fluorescently inactive 1a-TO1 construct exhibits turn-on fluorescent signal when bound to the hairpin form of $r(\text{G}_4\text{C}_2)^{\text{exp}}$, which is quenched upon displacement with small molecules interacting with the RNA. The bound structures of compound 4 to 5'-GGC-3' and 5'-CGG-3' sites were obtained by combining 2D NOESY NMR experiments with computational modeling (G represents the G residue within the 1×1 GG internal loops). **(c)** The degree of Förster resonance energy transfer (FRET) from 5'-FAM to 3'-TAMRA within the dual-labeled $r(\text{G}_4\text{C}_2)_4$ construct is monitored as a function of temperature in the presence and absence of small-molecule ligands. Derivative DB1273 stabilizes the G-quadruplex form of $r(\text{G}_4\text{C}_2)_4$ and exhibits FRET at higher temperatures relative to the vehicle control, i.e. higher melting temperature (T_m). **(d)** Binding of DPFp8 to the triple helix region of MALAT1 can be monitored by measuring the quenching of compound intrinsic fluorescence upon interaction with the nucleic acid.

fungal metabolism. This is therapeutically appealing, given that pathogenic yeasts represent a serious threat to patients with compromised immunity.

Starting from the ai5 γ II intron of *Saccharomyces cerevisiae*, Fedorova *et al.* [31] engineered a multiturnover ribozyme termed 'D135' capable of cleaving fluorescently quenched oligonucleotide RNA substrates that resemble the parental 5' splice site. A fluorescence-based HTS was performed on 10 000 molecules from commercially available libraries, including NCI, US Food and Drug Administration (FDA)-approved drugs, ENZO, ChemBridge, and ChemDiv. The initially identified benzylidene-benzofuran lead molecule was optimized via medicinal chemistry approaches unraveling structure–activity relationships (SAR) that ultimately led to Intronistat B (Fig. 2a). This derivative inhibited growth of *Saccharomyces cerevisiae* and *Candida parapsilosis* in the same bioactivity range as the established antifungal agent amphotericin B, by disrupting the splicing of the mitochondrially encoded cytochrome c oxidase I (COX1) gene, and was well tolerated in mammalian cells. In conclusion, the study emphasizes that commercially available libraries of small molecules contain derivatives that target ribozymes derived from pathogenic yeasts. Further studies in elucidating the exact binding site might offer novel opportunities to identify the conformational changes that block the activity of the ribozyme.

Dye displacement assay yields bioactive derivatives of the r(G₄C₂)^{exp} hairpin

Fluorescent intercalator displacement (FID) [33–35] uses turn-on fluorophores that exhibit enhanced fluorescence properties upon binding a macromolecular target. For example, thiazole orange (TO)-based dyes exhibit low fluorescent properties when freely diffused in solution, but the fluorescence is dramatically enhanced upon binding RNA because of lowering of the degrees of rotation. Therefore, SMIRNAs can be identified upon fluorescence quenching as the bound dye is displaced from the RNA target [36]. TO dyes can also be covalently linked to known RNA binders, whereby the small molecule will bring TO into the vicinity of the target RNA, yielding a fluorescent signal.

Intronic r(G₄C₂)^{exp} hexanucleotide repeat expansions within the *C9orf72* gene are the most common cause for genetically defined ALS and FTD, collectively termed 'c9ALS/FTD' [37,38]. Key pathologies responsible for the clinical manifestations of c9ALS/FTD are caused by RNA gain-of-function mechanisms of r(G₄C₂)^{exp}, such as the formation of RNA foci in the nucleus and the production of toxic dipeptide repeats (DPR) via repeat-associated non-ATG translation (RANT) in the cytosol, which ultimately lead to neuronal death. However, the precise RNA secondary structure(s) of r(G₄C₂)^{exp} that are responsible for the disease phenotypes are not well understood. Literature reports show that r(G₄C₂)^{exp} can form at least two structural folds in equilibrium [39–41], depending on the cations present in solution. Specifically, Na⁺ ions favor the hairpin form, comprising 1 \times 1 GG internal loops, whereas the addition of K⁺ ions completely shifts the equilibrium towards the formation of a thermodynamically stable G-quadruplex structure.

Focusing on the hairpin form, Wang *et al.* [42] identified small molecules targeting c9ALS/FTD pathology by means of an *in vitro* dye displacement assay using the 1a-TO1 conjugate. This encom-

passes the previously reported binder of r(G₄C₂)^{exp}, termed 1a, covalently attached to TO1 dye via a linker (Fig. 2b). By monitoring quenching of the 1a-TO1 signal upon displacement with a focused compound collection of 45 derivatives chemically similar to 1a, the authors identified the ellipticine derivative termed 'compound 4'. This derivative more potently bound r(G₄C₂)₈ over various RNA control sequences and reduced RANT in a r(G₄C₂)₆₆ transfected HEK293T disease model to a greater extent than 1a, an antisense oligonucleotide, and several known G-quadruplex binders. *In vitro*, compound 4 potently disrupted a deleterious RNA–protein interaction characterized in c9ALS/FTD cellular models, such as r(G₄C₂)^{exp}–hnRNP H, via a time-resolved FRET (TR-FRET) assay. Indeed, compound treatment released the sequestered hnRNP H protein from nuclear RNA foci in the r(G₄C₂)₆₆-transfected HEK293T disease model. Various biophysical techniques showed that the hairpin rather than the G-quadruplex conformation undergoes RANT and that compound 4 stabilizes the 1 \times 1 GG internal loops via stacking interactions (Fig. 2b). Mechanistically, the small molecule hinders the assembly of polysomes on the toxic transcript r(G₄C₂)₆₆ inhibiting RANT without affecting mRNA levels. In conclusion, the study indicates that the stabilization of the r(G₄C₂)^{exp} hairpin form is a therapeutically viable solution to develop novel lead medicines for c9ALS/FTD.

FRET-based melting assay yields bioactive derivatives of the r(G₄C₂)^{exp} G-quadruplex form

A third popular fluorescence-based screening approach relies on the FRET between two fluorescently active moieties. When found in proximity, the energy released upon exciting the donor fluorophore is transferred to the acceptor fluorophore, the emission of which is then recorded. Therefore, the lower the distance between the fluorophores, the stronger the energy transfer and the higher the emission recorded on the acceptor channel. Given that FRET reports changes in distances at the nanometer scale, it can be applied in various scenarios where conformational changes of the RNA molecule(s) under investigation are measured upon applying external stimuli, such as heat. Increasing the temperature over a wide range triggers the denaturation of the RNA structure and consequently lowers or abolishes the FRET signal.

Focusing on the G-quadruplex form of r(G₄C₂)₄, Simone *et al.* [43] used a FRET-based melting assay on 138 compounds to identify small-molecule stabilizers of this RNA fold. Using the FRET signal arising from the 5'-FAM and 3'-TAMRA dual-labeled r(G₄C₂)₄ construct to measure the melting temperature (T_m) in the presence of the derivatives, the authors identified three structurally related small molecules, DB1246, DB1247, and DB1273, (Fig. 2c) that stabilized r(G₄C₂)₄ over d(G₄C₂)₄. The most promising derivative, DB1273, successfully reduced the number of nuclear RNA foci in patient-derived induced pluripotent stem cell (iPSC)-derived motor and cortical neurons and lowered the dipeptide repeats poly(GP) levels with no cytotoxicity. In addition, compound treatment improved the survival of a c9ALS/FTD *Drosophila* model at different developmental stages by lowering the levels of poly(GP) and poly(GR) without affecting the RNA transcript, indicating an RNA-based mode of action.

In conclusion, both studies emphasize the importance of pursuing structurally and mechanistically well-characterized disease-

causing RNAs in compound-screening campaigns. The combination of target-based screening assays, such as dye-displacement, FRET, and TR-FRET, and bioactivity testing in physiologically relevant disease models can accelerate the development of c9ALS/FTD therapeutics in a more straightforward manner.

Exploiting intrinsic fluorescence for the identification of ligands against MALAT1

An additional fluorescence-based screening approach is based on monitoring the fluorescent properties of SMIRNAs. In this case, the signal of intrinsically fluorescent active ligands in solution is quenched upon interaction with the RNA due to various factors, such as conformational changes of the bound ligand or stacking with the internal nucleotides. This approach is particularly appealing because it does not need chemical derivatization of the ligand to attach a fluorescently active unit. The identification of a position suited for functionalization that will not perturb binding activity to the intended RNA target usually implies additional synthetic steps, which can often be cumbersome depending on the molecular complexity of the ligand. Therefore, intrinsically fluorescent small molecules can directly be applied in screening campaigns for assessing RNA binding and selectivity.

The lncRNA MALAT1 is overexpressed in numerous cancer models and its ablation was reported to decrease invasion and tumor growth [44,45]. Recent studies showed that MALAT1 transcript levels are governed by a specific region within the 3'-end that folds into a U-A-U triple helix structure, recently characterized by X-ray crystallography [46]. Destabilizing this region with small molecules represents a novel strategy to reduce the cellular stability of MALAT1, leading to its rapid degradation in cancers where this transcript is overexpressed [47]. Using the propensity of the diphenylfuran derivative furamidine (DPF) to bind 5'-AU/3'-UA base pairs [48], Donlic *et al.* [49] reported its medicinal chemistry optimization yielding DPFP8 (Fig. 2d). This interacted with the triple helix domain of MALAT1 *in vitro* more potently than control RNA and DNA sequences, as determined by the quenching of the intrinsic fluorescence of the compound. Interestingly, DPFP8 exhibited the most pronounced rod-like character among the entire series of synthesized derivatives, exhibiting a nearly planar conformation and dihedral angles that preclude intramolecular interactions between the functional groups and the aromatic rings. In conclusion, the report highlights the optimization of a previously reported triplex binder by combining lead optimization with 3D shape and conformational analysis that led to high affinity and selectivity towards the desired RNA target *in vitro*. Further studies are required to establish whether the optimized candidate DPFP8 modulates the transcript levels of MALAT1 by the proposed mechanism in disease-relevant cellular models. Interestingly, DPF was previously reported to potently bind r(AUUCU)^{exp} *in vitro* by targeting the 5'-AU/3'-UA base pairs [48]. An azide-functionalized DPF derivative was then used to generate a dimeric compound that potently corrected various phenotypes associated with spinocerebellar ataxia type 10 (SCA10) in patient-derived cells. Therefore, DPF is a versatile building block for designing and optimizing small molecules targeting various RNA structural motifs containing 5'-AU/3'-UA base pairs and U-A-U triple helices.

Small molecule microarray strategies

Small molecule microarrays (SMMS) represent a pivotal technology with major applications in target-based drug discovery campaigns. The principle relies on the covalent or noncovalent immobilization of small molecules on microchips depending on the chosen screening strategy. Thousands of small-molecule spots can be deposited in an array format on microarray slides, which are subsequently screened against fluorescently labeled biomacromolecules. Hit compounds can easily be identified by deconvoluting the spots where the target molecule is highly enriched.

Small-molecule microarray yields bioactive compounds targeting MALAT1

Using a SMM strategy, Abulwerdi *et al.* [50] reported the discovery of two structurally unrelated derivatives that target the triplex region of MALAT1 derived from mouse. Briefly, isocyanate-coated glass slides were reacted with the amino or hydroxy functional group of 26 229 commercially available derivatives, yielding small-molecule libraries immobilized on chip. These were incubated with the fluorescently labeled triple helix region of MALAT1 and spots exhibiting a high fluorescent signal were identified as hit compounds. Compound 5 and compound 16 (Fig. 3a) emerged as potential lead molecules after passing various selection criteria, including internal SMM screening campaigns against various hairpins, riboswitches, and others. The selected compounds reduced the expression levels of MALAT1 and the degree of branching morphogenesis in an organoid mouse model of mammary cancer. In conclusion, this study reports the robust application of SMMS against MALAT1, which yielded two structurally dissimilar small molecules biologically active in mouse organoid tumor models. Further studies are required to validate the RNA-centric model of action of these compounds, which will increase our understanding of how to rationally design small molecules that affect MALAT1 biology in relevant disease models.

Drug repurposing via library versus library screening (AbsorbArray)

A novel microarray-based screening technology was recently developed, termed 'AbsorbArray' (Fig. 3b). In this case, small-molecule compounds from commercially available libraries are noncovalently adhered on the surface of agarose-coated microarrays and screened against RNA motif libraries commonly found in ncRNAs. The lack of covalent attachment on the microarray slides is particularly appealing, because readily available compound libraries of small molecules can be applied on the chip without further derivatization, which might affect the binding mode to the RNA target(s). Compared with the traditional microarray approach, where each RNA target of interest is screened in a stepwise fashion, the RNA motif library versus small-molecule library screening format of AbsorbArray, termed 2D combinatorial screening (2DCS), probes an even greater number of interactions in a single step that will ultimately yield the preferred RNA motif for each individual small molecule. Therefore, compounds targeting RNA structural element(s) that are part of disease-causing RNAs can straightforwardly be identified together with their relative affinity to the entire RNA motif library.

The half-life of ncRNAs is orchestrated by a fine-tuned balance between synthesis and degradation and is correlated with various




FIGURE 3

Graphical representations of the small-molecule microarray strategies used to identify small molecules interacting with RNA. **(a)** Small molecules are covalently attached to the surface of a microchip using straightforward chemistries, followed by incubation with the fluorescently labeled triple helix region of MALAT1. After subsequent washing steps, the highly fluorescent spots are identified and hit molecules are deconvoluted. **(b)** Small-molecule libraries are absorbed on the agarose-coated surface of a chip. This is then incubated with a ^{32}P -radiolabeled RNA library of 3×2 internal loops, followed by extensive washing steps. Afterwards, the radioactive spots are isolated and the RNA targets are identified via RT-PCR and sequencing. This method provides the RNA motif–small molecule pair.

human diseases. In particular, miRNA-21 upregulation has been shown to contribute to several cancer pathologies, including lung carcinoma [51] and pancreatic ductal adenocarcinoma [52]. Therefore, lowering miRNA-21 levels by blocking its processing and subsequent maturation shuts down the activation of various downstream biological pathways modulated by this miRNA.

Velagapudi *et al.* [53] confirmed that the invasive phenotype of MDA-MB-231 triple-negative breast cancer cells can be ablated by the chemotherapeutic agent mitoxantrone by specifically targeting a key A-bulge within pre-miRNA-21, affecting its processing. AbsorbArray was performed on ~1000 compounds within the NIH Clinical Collection (NIH-CC), kinase- and RNA-focused libraries, and ~1024 RNA motifs comprising 3×2 asymmetric internal loops and bulges present in various cellular RNAs. The presence of competitor oligonucleotides eliminated nonspecific binders and enriched the selection of compounds binding strongly to defined RNA structural elements. The identification of highly confident

RNA motif small-molecule pairs was revealed by sequencing RNAs bound to the microarray chip and deconvoluted via a stringent statistical analysis tool, termed ‘high-throughput structure-activity relationships through sequencing’ (HiT-StARTS). This strategy revealed that mitoxantrone reliably binds the A bulge in the Dicer site of pre-miRNA-21 (Fig. 3b) inhibiting Dicer processing *in vitro* and in MDA-MB-231 cells. As a result, the levels of the tumor suppressor phosphatase and tensin homolog (PTEN) increased, ultimately leading to the ablation of the invasive phenotype of MDA-MB-231. RNA target modulation by mitoxantrone was confirmed by over-expressing pre-miRNA-21, which abolished the biological activity of this compound, and by target engagement using the Chemical-Crosslinking and Isolation by Pull-Down (Chem-CLIP) procedure.

In conclusion, this study highlights important conclusions for the field of drugging RNA with small molecules. First, AbsorbArray furnishes high-confidence small molecules binding disease-caus-




FIGURE 4

Graphical representations of the database search and affinity selection strategies used to identify small molecules interacting with RNA. **(a)** Inforna search reveals that Targapremir-210 (TGP-210) targets the Dicer site of miRNA-210 featuring a 1×1 CC internal loop; **(b)** A 214 375-member library on polymeric microbeads was spatially segregated allowing for spatial differentiation between cyclic γ -AA peptides (surface) and a corresponding linear tag (core). The beads were incubated with the fluorescently labeled oligonucleotide containing the UPF1-binding RNA sequence. Highly fluorescent beads were isolated, the linear tag was released from the beads, and its sequence deconvoluted via tandem mass spectrometry.

ing RNA structural motif(s) *in vitro*, which is appealing in drug repurposing campaigns. Second, the invasive phenotype of MDA-MB-231 can be ablated by mitoxantrone targeting a key RNA structural element of pre-miRNA-21, therefore validating an RNA-based mechanism of action in addition to inhibiting type II topoisomerase.

Database search strategies

Mining Inforna yields an inhibitor of miRNA-210 processing

The recent technological advances in various research areas, such as screening methodologies, sequencing, computational power, and bioinformatics, have yielded a wealth of information about targeting RNA with small molecules freely accessible online. As a result, tremendous efforts have been invested into compiling all this information in databases that researchers can use as starting points for testing biological hypotheses related to drugging RNA with small molecules. The Inforna platform merges RNA secondary structure prediction with the results obtained via 2DCS [54]. Upon simultaneously probing millions of possible RNA small-molecule interactions, valuable data are then extracted by means of stringent statistical analysis which ultimately yields high-throughput SAR between RNA motifs and small molecules. That is, for each disease-causing RNA structural motif, Inforna can

provide high-quality lead small molecule(s) as well as their relative affinity towards structurally similar and dissimilar secondary structures [54,55].

MiRNA-210 is a therapeutically relevant ncRNA associated with poor prognosis in numerous breast [56], lung [57] and pancreatic cancers [58]. In normal conditions (normoxia), hypoxia inducible factor 1 α (HIF-1 α) is rapidly degraded by the proteasome via prolyl hydroxylase (PHD) upon ubiquitination and subsequent degradation [59]. However, under hypoxic conditions (hypoxia), the increased expression of miRNA-210 downregulates glycerol-3-phosphate dehydrogenase 1-like (GPD1L), which in turn represses PHD and prevents the proteolytic degradation of HIF-1 α [60]. This mechanism promotes resistance to radiation treatments, and facilitates cell proliferation and survival in tumor environments, leading to tumor relapse [57]. Therefore, lowering the miRNA-210 levels by targeting its processing might represent a therapeutically viable solution.

Based on the Inforna mining, Costales *et al.* [61] identified the small molecule Targapremir-210 (TGP-210) as a high-confidence binder of the 1×1 CC internal loop within the Dicer site of pre-miRNA-210, thus blocking its processing *in vitro* and *in vivo* (Fig. 4a). As a result, TGP-210 treatment upregulated GPD1L,

decreased the stability of HIF-1 α , and inhibited tumor growth *in vivo* in a NOD/SCID mouse model. By performing target engagement experiments by means of Chem-CLIP, the authors then demonstrated that the phenotype was the result of the modulation of pre-miRNA-210 levels. The results showed that TGP-210 recognizes the pre-miRNA-210 Dicer site selectively *in vitro* and can distinguish between RNA targets that feature the same binding motif as pre-miRNA-210 based on the different expression levels. Additionally, profiling studies by RT-qPCR highlighted that only miRNA-210 was significantly affected among hypoxia-related miRNAs. In summary, this study exploited the differential expression levels of miRNA-210 in hypoxic versus normoxic conditions to selectively modulate the Dicer processing of pre-miRNA-210. Moreover, important insights related to the druggability of ncRNAs with small molecules have been revealed. For example, the degree of RNA target occupancy in cells is driven not only by the affinity of the small molecule to a particular RNA structural motif, but also by the expression levels of the RNAs that feature this binding site.

Affinity selection strategies

One-bead-two-compounds (OBTC) strategy for disrupting GAS5-UPF1 interaction

Affinity selection techniques represent powerful tools in modern drug discovery. Among them, the split-and-pool synthesis of one-bead-one-compound (OBOC) and one-bead-two-compounds (OBTC) libraries yield unique and structurally diverse compounds attached as multiple copies onto solid support. The beads decorated with individual compounds are then incubated with fluorescently labeled macromolecules followed by subsequent isolation of the beads exhibiting the highest fluorescent signal. This is followed by chemical release of the hit(s) and subsequent sequence deconvolution by mass spectrometry (MS) techniques. Although the entire procedure involves multiple steps, the OBOC and OBTC approaches with structurally diverse combinatorial libraries are useful in targeting orphan macromolecular targets.

Low levels of the lncRNA GAS5 in serum is considered as a potential biomarker for patients with type 2 diabetes mellitus (T2DM) [62]. Mechanistically, the GAS5 reduction blocks glucose uptake by regulating the expression levels of the insulin receptor in adipocytes. Therefore, increasing the GAS5 levels by inhibiting its degradation might stimulate insulin signaling. Its cellular levels are mediated by the regulator of nonsense transcripts 1 (UPF1) protein, a crucial component of the nonsense-mediated decay (NMD) pathway. Indeed, depletion of UPF1 led to GAS5 accumulation in cells, suggesting that interfering with the GAS5-UPF1 interaction is therapeutically viable.

Shi *et al.* [63] reported the first small-molecule disruptor of the GAS5-UPF1 lncRNA-protein interaction by applying an OBTC strategy. The authors generated a 214 375-member library that was incubated with the fluorescently labeled oligonucleotide containing the UPF1-binding RNA sequence of GAS5 in the presence of a \sim 1000-fold tRNA competitor. Highly fluorescent beads were isolated and sequence-deconvolution identified the macrocyclic derivative NP-C86 (Fig. 4b), exhibiting nanomolar binding affinity to lncRNA GAS5. Compound treatment restored the GAS5 levels in DM adipocytes without affecting

the UPF1 levels. Consequently, this reinstated glucose uptake upon insulin stimulation in cells as well as in *ex vivo* diabetic adipose tissue (AT) explants. In conclusion, the OBTC strategy yielded the macrocycle NP-C86, which reduced the turnover of lncRNA GAS5 by blocking its interaction with UPF1, offering a therapeutically viable and novel approach to restore glucose homeostasis.

New modalities to tackle RNA disease biology

In situ inhibitor synthesis driven by RNA templated oligomerization


The RNA r(CUG)^{exp} within the 3'-UTR of the dystrophin myotonia protein kinase (DMPK) mRNA transcript causes DM1. In patients with DM1, hundreds to thousands of such repeats form hairpin structures featuring 1 \times 1 UU internal loops, which sequester various RNA-binding proteins, such as MBNL1. This RNA gain-of-function mechanism ultimately leads to dysregulation of the RNA splicing processes and defects in nucleocytoplasmic transport, causing muscle atrophy and myotonia along with numerous other multisystemic health issues. Significant resources were invested into developing chemical tools to probe and correct the dysfunction of r(CUG)^{exp} by targeting the repetitive 1 \times 1 UU internal loops with dimeric small molecules. A recent example published by Rzuczek *et al.* [64] describes 2H-K4NMeS, a dimeric chemical probe that potently targets r(CUG)^{exp} and relieves various DM1-associated phenotypes (Fig. 5a). These effects are mediated by selectively engaging the r(CUG)^{exp} in cells, as shown by the target engagement experiments via Chem-CLIP. Using this information, the initial 2H-K4NMeS was equipped with alkyne and azide handles placed at optimal distances that are prone to *in situ* oligomerization by means of click chemistry when adjacently bound to RNA (Fig. 5b). As a result, the oligomeric product achieved 100-fold increased potency compared with the control probe. Interestingly, this RNA-catalyzed click approach also enabled the RNA templated synthesis of FRET sensors that not only confirmed target engagement, but also imaged the assembly process at the r(CUG)^{exp} sites in cells (Fig. 5b). This work also described the development of small-molecule nucleic acid profiling by cleavage applied to RNA (Ribo-SNAP), which exploits the cleavage activity towards nucleic acids of the natural product Bleomycin A5. When covalently linked to 2H-K4NMeS, cleavage occurs at the RNA r(CUG)^{exp} sites, depleting the RNA levels, which dramatically corrects the splicing defects in DM1 cellular models (Fig. 6a). Together, these synergistic chemical biology approaches can be applied to small molecules that potently and selectively bind repetitive sequences and could be applied to more than 30 microsatellite repeat expansions, many of which are still orphans of lead medicines.

Cleavage of miRNA-96 by RNase L recruitment


MiRNA-96 is highly expressed in breast cancers and represents a crucial biological hub that represses the proapoptotic transcription factor Forkhead box protein O1 (FOXO1), leading to cancer cell proliferation and tumor progression [65]. Therefore, ablating the levels of this ncRNA might provide therapeutic benefit. Along these lines, Costales *et al.* [66] reported the development of a RIBOnuclease Targeting Chimera (RIBOTAC) strategy that

New modalities to tackle RNA disease biology

(a) Bivalent targeting of toxic r(CUG)^{exp} for the rescue of MBNL1



(b) *In situ* RNA-templated click reaction



Drug Discovery Today

FIGURE 5


Graphical representation of emerging modalities that potentially correct aberrant phenotypes triggered by disease-causing RNAs. **(a)** Dimeric compounds potentially bind r(CUG)^{exp} and release sequestered MBNL1. **(b)** Dimeric compounds equipped with azide and alkyne functional groups, respectively, undergo *in situ* oligomerization templated by the disease-causing RNA [e.g. r(CUG)^{exp}]. This process can be followed in cells by means of a FRET sensor generated from dimeric compounds equipped with FRET-compatible fluorophores.

harnesses ribonuclease L (RNase L) to specifically cleave miRNA-96 (Fig. 6b). RNase L is a crucial component of the antiviral immune response and is ubiquitous in all cells in an inactive monomeric state. Its activation occurs via dimerization when binding 2'-5' oligoadenylate [2'-5'-poly(A), 2'-5'-A₄], the levels of which are increased upon viral infection. Therefore, the 2'-5'-A₄ levels dictate regardless of whether RNase L is active. The authors exploited this cellular mechanism using chemical probe 2 (Fig. 6b), comprised of the small molecule Targaprimir-96 (TGP-96) conjugated to 2'-5'-A₄, the dimerization inducer of RNase L. The latter recruits endogenously present RNase L and, therefore, activates its nuclease activity proximal to the pri-miRNA-96 binding site of TGP-96 (Fig. 6b). Therefore, chemical probe 2 selectively decreases the levels of pri-miRNA-96 and, consequently, miRNA-96 in MDA-MB-231 cells, ablating its invasive phenotype. Finally, compound treatment significantly

increased the levels of FOXO1 and selectively triggered apoptosis of the MDA-MB-231 cells in a miRNA-96-dependent manner. In conclusion, the study reports a novel strategy to cleave ncRNAs that harnesses the ribonucleic acid degradation machinery within cells. This approach promises the development of custom RNA degraders to direct the RNase L nuclease activity in the proximity of almost any small molecule that targets therapeutically relevant ncRNAs.

Concluding remarks

Major progress in SMIRNAs within the past few years has elevated RNA among the therapeutically relevant biological targets to include in drug discovery campaigns [17,67]. Indeed, the field has accelerated at a rapid pace because of a better understanding of RNA structure and biology, and technological advancements in areas, such as synthetic methodologies, commercial avail-

**FIGURE 6**

Graphical representation of emerging modalities that cleave disease-causing RNAs. **(a)** The dimeric molecule 2H-K4NMeS covalently linked with the nucleic acid cleavage moiety Bleomycin A5 efficiently cleaves r(CUG)^{exp}. **(b)** The dimeric molecule Targaprimir-96 (TGP-96) covalently linked to the RNase L dimerization unit 2'-5'-A₄ efficiently cleaves miRNA-96. This is achieved by the endogenous nuclease activity of RNase L, which is placed in close proximity to miRNA-96 by the RNA-binding module TGP-96.

ability of compound libraries, computational power, and sequencing.

Including RNA among the myriad biologically relevant drug targets expands the possibilities to tackle human diseases triggered by aberrant function of RNA motifs with small molecules. However, one of the main challenges is the efficient exploration of the currently available chemical space that engage disease-causing RNA structural elements. Currently, commercially available chemical libraries are enriched with chemical probes and small molecules optimized against commonly drugged protein targets, such as G-protein-coupled receptors (GPCRs) and kinases. In addition, not only clinically approved drugs, but also derivatives that lacked clinical efficiency are continuously pursued as new leads in drug repurposing campaigns. Therefore, an

immediate approach is to efficiently repurpose clinically relevant candidates towards diseases that are triggered by aberrant function of RNA. A recent study showed that approved drugs can modulate the oncogenic noncoding miRNA-21 for therapeutic gain [53], highlighting the AbsorbArray technique as a straightforward strategy to repurpose the already available chemical matter to novel therapeutic indications. In addition, because these chemotypes were optimized to bind protein targets, they represent a solid ground to apply medicinal chemistry approaches to repurpose their cellular profile towards modulating disease-causing RNAs while minimizing the off-target effects in a proteome- and transcriptome-wide fashion.

The main challenge for chemists and chemical biologists remains the *de novo* discovery of novel chemical matter that efficiently

populates the biologically relevant chemical space interacting with RNA motifs, which will steadily increase. The challenge will be the development of robust technologies to provide initial hits and assess the druggability of RNA motifs with small molecules. First, screening virtual chemical libraries allows a straightforward approach to assess how suitable the currently assembled and explored chemical space is for targeting the noncoding transcriptome. This process has remained elusive because of a lack of understanding of how small molecules affect RNA conformational changes and dynamics upon binding. As a result, currently applied methods lack consistency and robustness in providing candidates that can be experimentally confirmed. This drawback can be addressed by performing VS campaigns using dynamic ensembles of rigorously characterized RNA structures that better capture the conformational heterogeneity and dynamics of the RNA of interest, therefore providing high-quality hits. In addition, developing reliable force fields and molecular dynamics simulations of RNA structure(s) [68] will provide good starting points towards efficient VS campaigns where the RNA of interest lacks structural characterization. Second, various HTS techniques are currently applicable and well established to robustly identify SMIRNAs (Table S1 in the supplemental information online), including ligand displacement assays [29,34,35], NMR-based methods [69], catalytic enzyme-linked click chemistry assay (cat-ELCCA) [70,71], automated ligand identification system (ALIS) via affinity selection-mass spectrometry (AS-MS) [72,73], and microarray formats, such as SMMs [74], 2DCS [75], and AbsorbArray [53]. For example, compound-immobilized chips can be used either in sequential RNA target-based screening, as in the case of SMMs, or in a massively parallel format with RNA motif libraries. Whereas in the former, lead molecules against a single target can be determined, the 2DCS and AbsorbArray simultaneously probe RNA motifs against small-molecule libraries. Such screening campaigns usually yield an enormous amount of data, for which the continuous improvement of bioinformatics tools, such as HiT-StARTS, Informa [54,55], and Pattern Recognition of RNA by Small Molecules (PRRSM) [76], is crucial to provide chemotype centric hypotheses to efficiently and selectively target RNA motifs. These efforts will need to be followed by synthetic efforts towards optimization, generation of SAR studies, and, if possible, structural characterization of the RNA–small molecule interaction to better understand the underlying principles of the molecular recognition event as well as its impact on the stability and/or dynamics of the RNA–small molecule complex. In particular, various 1D- and 2D-NMR methods have been used to reveal atomistic details of the RNA–small molecule interaction [77–79].

These efforts must be accompanied by rigorous target engagement and profiling studies in cells to demonstrate the RNA-centric mechanism of action [80]. The chemical biology community has been actively addressing this issue by developing technologies, such as Chem-CLIP, Ribo-SNAP, and RIBOTAC, which are well suited for this purpose. Such chemical tools were recently used to map binding sites of small molecules to RNAs, thus correlating the data obtained *in vitro* and *in vivo*. Therefore, the interrogation of the biological effects of small molecules both transcriptome and proteome wide will provide a more in-depth understanding of their interaction with biological systems and clearly delineate a protein- and/or RNA-centric mode of action. When combined with RNA sequencing [81], these modalities could be applied to target identification campaigns following phenotypic screens with already existing drugs

or *de novo* chemical matter, whereby no protein target was accurately assigned to the hit molecule(s). Although an exact mode of action is not necessary for clinical approval, the identification early on of possible transcriptome-wide RNA off-target effects can mitigate the risk of failure in more advanced stages of clinical trials.

Given that RNA structure is fundamentally different to protein structure, the principles of potently and selectively targeting disease causing RNAs might differ and new concepts along these lines are starting to emerge. For example, multipronged approaches to study RNA small molecule interactions will allow researchers to: (i) fully understand the molecular recognition event between the RNA motif and the small molecule; and (ii) identify the most relevant conformational changes that trigger a biological response. On the one hand, this will require a comprehensive understanding of the physicochemical properties of the RNA structural motif(s), such as electropositive and negative surfaces, impact of the closing base pairs, hydration, surrounding metal ions, or location of the motif within the RNA helix. More important is how these effects impact the conformational heterogeneity landscape (i.e., the interconversion and distribution between local and global minima states in the apo and ligand bound form). On the other hand, a good understanding of the physicochemical and conformational properties of the small molecule(s) is equally important. For example, compounds with a rod-like character were highlighted to exhibit affinity and selectivity towards particular RNA targets [82]. In addition, conformational parameters that dictate small molecule preorganization and planarity were considered when optimizing the SMN2 splicing agent Risdiplam [83], indicating that SMIRNAs and/or pre-mRNA might occupy a privileged location of the chemical space that might or might not overlap with the chemical matter targeting the proteome. Moreover, all these efforts must be analyzed for each RNA structural motif–small molecule pair to better assess the druggability of RNA-binding site as well as the identification of the chemotypes that trigger biologically relevant conformational changes.

We are only at the beginning of truly understanding the structural prerequisites for developing potent and selective SMIRNAs, which might require a paradigm change of the drug-likeness concept [84,85]. Some of the prominent examples presented here, such as peptides, macrocycles, and dimeric molecules, showed efficient correction of the phenotype(s) triggered by the disease-causing RNA, but do not obey Lipinski's rule of five [86,87]. Despite this, dimeric molecules exhibit improved binding and selectivity towards RNA repeat expansions compared to the monomeric units, therefore significantly lowering the dose needed for therapeutic gain. In a recent example, Angelbello *et al.* [88] showed that intraperitoneally delivered Cugamycin selectively cleaved r(CUG)^{exp} in a DM1 preclinical mouse model. Therefore, future interrogation campaigns of the beyond rule of five chemical space as well as optimization efforts will reveal novel ways to address and overcome the physicochemical properties featured by these compound classes for therapeutic benefit [89–91].

Drugging RNA is not limited to the identification and characterization of SMIRNAs. The continuous need to fulfill unmet therapeutic needs revealed new chemical tools that comprise of RNA binders covalently linked with either natural products or recruiting units of cellular components of the RNA degrada-

tion machinery to manipulate RNA function and modulate biological processes. Recent development of PROTAC [92] and its fast-paced development towards *in vivo* studies [93] was followed within only a few years later by RIBOTAC [66] for targeted degradation of RNAs via RNase L recruitment, opening avenues to provide new and effective therapeutic modalities [94,95] arising from the beyond rule of five chemical space [96]. Together with Ribo-SNAP, these new modalities not only achieve a more effective therapeutic effect because the target RNA is ablated, but both can also be used to confirm target engagement, map binding sites, and perform profiling studies *in vitro* and *in vivo* in a transcriptome-wide fashion [88]. Given their modular assembly, the units responsible for RNA cleavage (Bleomycin A5 and the 2'-5'-A₄ part of Ribo-SNAP, and RIBOTAC respectively) can be attached to almost any small molecule, allowing the interrogation of target occupancy in a transcriptome-wide fashion. This will provide important insights into how target occupancy by various chemotypes targeting the same RNA motif correlates with quantitative functional pharmacological effects *in vitro* and *in vivo*. Ultimately, such studies will comprehensively assess the chemotype–RNA target–phenotype interplay, leading to an improved understanding of the pharmacokinetic and pharmacodynamic properties and, therefore, to a better projection of the dose to the clinic.

We are at the cusp of deciphering the principles of effective small-molecule modulation of RNA targets. This could improve

the efficiency of existing treatments, extend therapeutic options for currently orphan diseases, and potentially improve the therapeutic portfolio of already existing disorders by targeting novel ncRNAs. Recent examples, including the sensitization of cell lines to already approved anticancer treatments [97], reprogramming oncogenic circuits [61], targeted degradation of ncRNAs [98], and the first examples of drugging lncRNAs [49,50,63] are setting the stage to a bright future towards more rational drug design and discovery campaigns against ncRNAs.

Acknowledgments

We thank the National Institutes of Health for funding (RO1-GM097455-07, DP1-NS096898, and PO1-NS099114). A.U. acknowledges the financial support received from the Deutsche Forschungsgemeinschaft (DFG) and the ALS Association (ALSA). S.V.-D. thanks the Fonds de Recherche du Québec-Nature et Technologie (FRQNT) for the Postdoctoral research scholarship. The authors are thankful to Jonathan L. Chen, Hafeez S. Haniff, Jessica L. Childs-Disney and the members of the Disney lab for the valuable input and helpful discussions that shaped the final version of the manuscript.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.drudis.2019.06.019>.

References

- Howe, J.A. *et al.* (2015) Selective small-molecule inhibition of an RNA structural element. *Nature* 526, 672
- Naryshkin, N.A. *et al.* (2014) SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. *Science* 345, 688–693
- Palacio, J. *et al.* (2015) SMN2 splice modulators enhance U1–pre-mRNA association and rescue SMA mice. *Nat. Chem. Biol.* 11, 511
- Barnwal, R.P. *et al.* (2017) Applications of NMR to structure determination of RNAs large and small. *Arch. Biochem. Biophys.* 628, 42–56
- Bevilacqua, P.C. and Blose, J.M. (2008) Structures, kinetics, thermodynamics, and biological functions of RNA hairpins. *Annu. Rev. Phys. Chem.* 59, 79–103
- Chavali, S.S. *et al.* (2019) Face-time with TAR: Portraits of an HIV-1 RNA with diverse modes of effector recognition relevant for drug discovery. *J. Biol. Chem.* 294, 9326–9341
- Thomas, J.R. and Hergenrother, P.J. (2008) Targeting RNA with small molecules. *Chem. Rev.* 108, 1171–1224
- The, E.P.C. *et al.* (2012) An integrated encyclopedia of DNA elements in the human genome. *Nature* 489, 57
- Ozsolak, F. and Milos, P.M. (2010) RNA sequencing: advances, challenges and opportunities. *Nat. Rev. Genet.* 12, 87
- Andrews, R.J. *et al.* (2017) RNAStructureDB: a genome-wide database for RNA structural inference. *Sci. Rep.* 7, 17269
- Kubota, M. *et al.* (2015) Progress and challenges for chemical probing of RNA structure inside living cells. *Nat. Chem. Biol.* 11, 933
- Mathews, D.H. *et al.* (2004) Incorporating chemical modification constraints into a dynamic programming algorithm for prediction of RNA secondary structure. *Proc. Natl. Acad. Sci. U. S. A.* 101, 7287–7292
- Sun, L. *et al.* (2019) RNA structure maps across mammalian cellular compartments. *Nat. Struct. Mol. Biol.* 26, 322–330
- Mustoe, A.M. *et al.* (2018) Pervasive regulatory functions of mRNA structure revealed by high-resolution SHAPE probing. *Cell* 173, 181–195
- Wu, X. and Bartel, D.P. (2017) Widespread influence of 3'-end structures on mammalian mRNA processing and stability. *Cell* 169, 905–917
- Langdon, E.M. *et al.* (2018) mRNA structure determines specificity of a polyQ-driven phase separation. *Science* 360, 922–927
- Disney, M.D. *et al.* (2018) Drugging the RNA world. *Cold Spring Harb. Perspect. Biol.* 10, a034769
- Donlic, A. and Hargrove, A.E. (2018) Targeting RNA in mammalian systems with small molecules. *Wiley Interdiscip. Rev. RNA* 9, e1477
- Rizvi, N.F. and Smith, G.F. (2017) RNA as a small molecule druggable target. *Bioorg. Med. Chem. Lett.* 27, 5083–5088
- Shortridge, M.D. *et al.* (2018) An ultra-high affinity ligand of HIV-1 TAR reveals the RNA structure recognized by P-TEFb. *Nucleic Acids Res.* 47, 1523–1531
- Adegbuyi, A. *et al.* (2017) Proteins containing expanded polyglutamine tracts and neurodegenerative disease. *Biochemistry* 56, 1199–1217
- Zhang, Q. *et al.* (2016) Assessing a peptidyl inhibitor-based therapeutic approach that simultaneously suppresses polyglutamine RNA- and protein-mediated toxicities in patient cells and *Drosophila*. *Dis. Mod. Mech.* 9, 321–334
- Salmon, L. *et al.* (2014) Advances in the determination of nucleic acid conformational ensembles. *Annu. Rev. Phys. Chem.* 65, 293–316
- Ganser, L.R. *et al.* (2018) High-performance virtual screening by targeting a high-resolution RNA dynamic ensemble. *Nat. Struct. Mol. Biol.* 25, 425–434
- Parkesh, R. *et al.* (2012) Design of a bioactive small molecule that targets the myotonic dystrophy type 1 RNA via an RNA motif–ligand database and chemical similarity searching. *J. Am. Chem. Soc.* 134, 4731–4742
- Angelbello, A.J. *et al.* (2016) Development of pharmacophore models for small molecules targeting RNA: application to the RNA repeat expansion in myotonic dystrophy type 1. *Bioorg. Med. Chem. Lett.* 26, 5792–5796
- Irwin, J.J. *et al.* (2012) ZINC: a free tool to discover chemistry for biology. *J. Chem. Inf. Model.* 52, 1757–1768
- Irwin, J.J. and Shoichet, B.K. (2005) ZINC—a free database of commercially available compounds for virtual screening. *J. Chem. Inf. Model.* 45, 177–182
- Patwardhan, N.N. *et al.* (2019) Fluorescent peptide displacement as a general assay for screening small molecule libraries against RNA. *Org. Biomol. Chem.* 17, 1778–1786
- Matarlo, J.S. *et al.* (2019) The natural product butylcycloheptyl prodigiosin binds pre-miR-21, inhibits dicer-mediated processing of Pre-miR-21, and blocks cellular proliferation. *Cell Chem. Biol.* XX, YYY–ZZZ
- Fedorova, O. *et al.* (2018) Small molecules that target group II introns are potent antifungal agents. *Nat. Chem. Biol.* 14, 1073–1078
- Lambowitz, A.M. and Zimmerly, S. (2011) Group II introns: mobile ribozymes that invade DNA. *Cold Spring Harb. Perspect. Biol.* 3, a003616
- Zhang, J. *et al.* (2010) Fluorescent indicator displacement assay for ligand–RNA interactions. *J. Am. Chem. Soc.* 132, 3660–3661
- Wicks, S.L. and Hargrove, A.E. (2019) Fluorescent indicator displacement assays to identify and characterize small molecule interactions with RNA. *Methods* XX, YYY–ZZZ

- 35 Asare-Okai, P.N. and Chow, C.S. (2011) A modified fluorescent intercalator displacement assay for RNA ligand discovery. *Anal. Biochem.* 408, 269–276
- 36 Tran, T. and Disney, M.D. (2012) Identifying the preferred RNA motifs and chemotypes that interact by probing millions of combinations. *Nat. Commun.* 3, 1125
- 37 Mori, K. *et al.* (2013) The c9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTL/ALS. *Science* 339, 1335–1338
- 38 DeJesus-Hernandez, M. *et al.* (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. *Neuron* 72, 245–256
- 39 Su, Z. *et al.* (2014) Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. *Neuron* 83, 1043–1050
- 40 Taylor, J.P. (2014) G-quadruplex poses quadruple threat. *Nature* 507, 175
- 41 Haeusler, A.R. *et al.* (2014) C9orf72 nucleotide repeat structures initiate molecular cascades of disease. *Nature* 507, 195
- 42 Wang, Z.-F. *et al.* (2019) The hairpin form of r(G₄C₂)^{exp} in c9ALS/FTD is repeat-associated non-ATG translated and a target for bioactive small molecules. *Cell Chem. Biol.* 26, 179–190
- 43 Simone, R. *et al.* (2018) G-quadruplex-binding small molecules ameliorate c9orf72 FTD/ALS pathology *in vitro* and *in vivo*. *EMBO Mol. Med.* 10, 22–31
- 44 Gutschner, T. *et al.* (2013) The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. *Cancer Res.* 73, 1180–1189
- 45 Arun, G. *et al.* (2016) Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. *Genes Dev.* 30, 34–51
- 46 Brown, J.A. *et al.* (2014) Structural insights into the stabilization of MALAT1 noncoding RNA by a bipartite triple helix. *Nat. Struct. Mol. Biol.* 21, 633–640
- 47 Amodio, N. *et al.* (2018) MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches. *J. Hematol. Oncol.* 11, 63
- 48 Yang, W.-Y. *et al.* (2016) Design of a bioactive small molecule that targets r(AUUCU) repeats in spinocerebellar ataxia 10. *Nat. Commun.* 7, 11647
- 49 Donlic, A. *et al.* (2018) Discovery of small molecule ligands for MALAT1 by tuning an RNA-binding scaffold. *Angew. Chem. Int. Ed.* 57, 13242
- 50 Abulwerdi, F.A. *et al.* (2019) Selective small-molecule targeting of a triple helix encoded by the long noncoding RNA, MALAT1. *ACS Chem. Biol.* 14, 223–235
- 51 Seike, M. *et al.* (2009) MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. *Proc. Natl. Acad. Sci. U. S. A.* 106, 12085–12090
- 52 du Rieu, M.C. *et al.* (2010) MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. *Clinical Chem.* 56, 603–612
- 53 Velagapudi, S.P. *et al.* (2018) Approved anti-cancer drugs target oncogenic non-coding RNAs. *Cell Chem. Biol.* 25, 1086–1094
- 54 Velagapudi, S.P. *et al.* (2014) Sequence-based design of bioactive small molecules that target precursor microRNAs. *Nat. Chem. Biol.* 10, 291
- 55 Disney, M.D. *et al.* (2016) Inforna 2.0: a platform for the sequence-based design of small molecules targeting structured RNAs. *ACS Chem. Biol.* 11, 1720–1728
- 56 Foekens, J.A. *et al.* (2008) Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. *Proc. Natl. Acad. Sci. U. S. A.* 105, 13021–13026
- 57 Grosso, S. *et al.* (2013) MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. *Cell Death Dis.* 4, e544
- 58 Greither, T. *et al.* (2010) Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. *Int. J. Cancer* 126, 73–80
- 59 Maxwell, P.H. *et al.* (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. *Nature* 399, 271
- 60 Kelly, T.J. *et al.* (2011) A hypoxia-induced positive feedback loop promotes hypoxia-inducible factor 1 α stability through miR-210 suppression of glycerol-3-phosphate dehydrogenase 1-like. *Mol. Cell. Biol.* 31, 2696–2706
- 61 Costales, M.G. *et al.* (2017) Small molecule inhibition of microRNA-210 reprograms an oncogenic hypoxic circuit. *J. Am. Chem. Soc.* 139, 3446–3455
- 62 Carter, G. *et al.* (2015) Circulating long noncoding RNA GASS levels are correlated to prevalence of type 2 diabetes mellitus. *BBA Clin.* 4, 102–107
- 63 Shi, Y. *et al.* (2019) Stabilization of lncRNA GASS by a small molecule and its implications in diabetic adipocytes. *Cell Chem. Biol.* 26, 319–330
- 64 Rzuczek, S.G. *et al.* (2016) Precise small-molecule recognition of a toxic CUG RNA repeat expansion. *Nat. Chem. Biol.* 13, 188
- 65 Guttilla, I.K. and White, B.A. (2009) Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. *J. Biol. Chem.* 284, 23204–23216
- 66 Costales, M.G. *et al.* (2018) Small molecule targeted recruitment of a nuclease to RNA. *J. Am. Chem. Soc.* 140, 6741–6744
- 67 Connelly, C.M. *et al.* (2016) The emerging role of RNA as a therapeutic target for small molecules. *Cell Chem. Biol.* 23, 1077–1090
- 68 Poner, J. *et al.* (2018) RNA structural dynamics as captured by molecular simulations: a comprehensive overview. *Chem. Rev.* 118, 4177–4338
- 69 Garavís, M. *et al.* (2014) Discovery of selective ligands for telomeric RNA G-quadruplexes (TERRA) through 19F-NMR based fragment screening. *ACS Chem. Biol.* 9, 1559–1566
- 70 Garner, A.L. (2018) cat-ELCCA: catalysing drug discovery through click chemistry. *Chem. Commun.* 54, 6531–6539
- 71 Lorenz, D.A. *et al.* (2018) Development and implementation of an HTS-compatible assay for the discovery of selective small-molecule ligands for pre-microRNAs. *SLAS DISCOVERY: Adv. Life Sci. R&D* 23, 47–54
- 72 Rizvi, N.F. *et al.* (2018) Discovery of selective RNA-binding small molecules by affinity-selection mass spectrometry. *ACS Chem. Biol.* 13, 820–831
- 73 Flusberg, D.A. *et al.* (2019) Identification of G-quadruplex-binding inhibitors of Myc expression through affinity selection–mass spectrometry. *SLAS DISCOVERY: Adv. Life Sci. R&D* 24, 142–157
- 74 Connelly, C.M. *et al.* (2017) Discovery of RNA binding small molecules using small molecule microarrays. In *Small Molecule Microarrays: Methods and Protocols* (Uttamchandani, M. and Yao, S.Q., eds), pp. 157–175, Springer
- 75 Tran, T. and Disney, M.D. (2010) Two-dimensional combinatorial screening of a bacterial rRNA A-site-like motif library: defining privileged asymmetric internal loops that bind aminoglycosides. *Biochemistry* 49, 1833–1842
- 76 Eubanks, C.S. *et al.* (2019) Visualizing RNA conformational changes via pattern recognition of RNA by small molecules. *J. Am. Chem. Soc.* 141, 5692–5698
- 77 Thompson, R.D. *et al.* (2019) NMR characterization of RNA small molecule interactions. *Methods* XX, YYY–ZZZ
- 78 Rinnenthal, J. *et al.* (2011) Mapping the landscape of RNA dynamics with NMR spectroscopy. *Acc. Chem. Res.* 44, 1292–1301
- 79 Mustoe, A.M. *et al.* (2014) Hierarchy of RNA functional dynamics. *Annu. Rev. Biochem.* 83, 441–466
- 80 Disney, M.D. (2019) Perspectives on targeting RNA with small molecules to capture opportunities at the intersection of chemistry, biology, and medicine. *J. Am. Chem. Soc.* 141, 6776–6790
- 81 Ye, C. *et al.* (2018) DRUG-seq for miniaturized high-throughput transcriptome profiling in drug discovery. *Nat. Commun.* 9, 4307
- 82 Morgan, B.S. *et al.* (2017) Discovery of key physicochemical, structural, and spatial properties of RNA-targeted bioactive ligands. *Angew. Chem. Int. Ed.* 56, 13498–13502
- 83 Ratni, H. *et al.* (2018) Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). *J. Med. Chem.* 61, 6501–6517
- 84 Mignani, S. *et al.* (2018) Present drug-likeness filters in medicinal chemistry during the hit and lead optimization process: how far can they be simplified? *Drug Discov. Today* 23, 605–615
- 85 Shultz, M.D. (2019) Two decades under the influence of the rule of five and the changing properties of approved oral drugs. *J. Med. Chem.* 62, 1701–1714
- 86 Lipinski, C.A. (2004) Lead- and drug-like compounds: the rule-of-five revolution. *Drug Discov. Today: Technol.* 1, 337–341
- 87 Zhang, M.-Q. and Wilkinson, B. (2007) Drug discovery beyond the 'rule-of-five'. *Curr. Opin. Biotechnol.* 18, 478–488
- 88 Angelbello, A.J. *et al.* (2019) Precise small-molecule cleavage of an r(CUG) repeat expansion in a myotonic dystrophy mouse model. *Proc. Natl. Acad. Sci. U. S. A.* 116, 7799–7804
- 89 Doak, Bradley C. *et al.* (2014) Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. *Chem. Biol.* 21, 1115–1142
- 90 DeGoey, D.A. *et al.* (2018) Beyond the rule of 5: lessons learned from AbbVie's drugs and compound collection. *J. Med. Chem.* 61, 2636–2651
- 91 Poongavanam, V. *et al.* (2018) Opportunities and guidelines for discovery of orally absorbed drugs in beyond rule of 5 space. *Curr. Opin. Chem. Biol.* 44, 23–29
- 92 Cromm, P.M. and Crews, C.M. (2017) Targeted protein degradation: from chemical biology to drug discovery. *Cell Chem. Biol.* 24, 1181–1190
- 93 Sun, X. *et al.* (2019) A chemical approach for global protein knockdown from mice to non-human primates. *Cell Discov.* 5, 10
- 94 Valeur, E. *et al.* (2017) New modalities for challenging targets in drug discovery. *Angew. Chem. Int. Ed.* 56, 10294–10323
- 95 Valeur, E. and Jimonet, P. (2018) New modalities, technologies, and partnerships in probe and lead generation: enabling a mode-of-action centric paradigm. *J. Med. Chem.* 61, 9004–9029
- 96 Edmondson, S.D. *et al.* (2019) Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: recent progress and future challenges. *Bioorg. Med. Chem. Lett.* 29, 1555–1564
- 97 Costales, M.G. *et al.* (2019) A designed small molecule inhibitor of a non-coding RNA synthesizes HER2 negative cancers to Herceptin. *J. Am. Chem. Soc.* 141, 2960–2974
- 98 Costales, M.G. *et al.* (2019) Targeted degradation of a hypoxia-associated non-coding RNA enhances the selectivity of a small molecule interacting with RNA. *Cell Chem. Biol.* XX, YYY–ZZZ